The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization.

Slides:

Advertisements

Similar presentations

Advanced Heart Failure and the Role of Mechanical Circulatory Support

Advertisements

EMPHO Public Health Intelligence Training Course Case study “Reaching hard to reach groups” Yesmean Khalil 5 th December 2006.

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Dr. Ananda Gunewardena1 Help Treat Chronic Renal Failure in Sri-Lanka An Appeal by Sri-Lankan Physicians.

Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.

1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.

Ian Graham et al. European Heart Journal 2007;28:

Quality of Care and Outcomes in Patients with Diabetes Hospitalized with Ischemic Stroke Findings From Get With The Guidelines-Stroke Reeves MJ; Vaidya.

Background: Heart failure (HF) is an incurable life-long disease with poor prognosis. Symptoms such as dyspnea cause limitation in patients’ daily life.

Heart Failure Khalid F AlHabib.MBBS.FRCPC Cardiology Consultant King Fahad Cardiac Centre King Saud University Wednesday, September 02, 2015Wednesday,

Heart Failure: From Failure to Success

Health Care Costs Associated with Chronic Kidney Disease in Patients with Type II Diabetes Zita Shiue, MD Internal Medicine, R3 Chief of Medicine Conference.

Current Management of Heart Failure GP clinical update 17 th June 2015 Dr Raj Bilku Consultant Cardiologist Clinical Lead Cardiology QEH.

Patient education tools are key to the follow- up of chronic heart failure patients.

The Value Of In-vitro Diagnostics Healthcare challenges in the 21 st century for governments & hospitals & how in-vitro diagnostics can contribute to overcoming.

Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,

Clinical Outcomes with Newer Antihyperglycemic Agents

New Zealand Cardiology Wards and Adventures Taylor Myers Locke.

Multiple risk factors raise ischaemic stroke risk comparable to AF in the elderly: A large Chinese insurance analysis from 425,600 Chinese individuals.

Section 3: CKD, CVD and mortality. Cardiovascular diseases in CKD patients Damage to the heart (Uraemic cardiomyopathy ) Damage to the arteries (Uraemic.

Chronic Kidney Disease (CKD) Epidemiology A NEW EPIDEMIC: CHRONIC KIDNEY DISEASE IN GENERAL POPULATION REAL PREVALENCE AND RELATED FACTORS Josep M. Galceran,

Group 7 Burden of disease in Brazil. KEY HEALTH INDICATORS Years of life lost (YLLs): Years of life lost due to premature mortality. Years lived with.

Academy Health Annual Meeting, Orlando, June 2007 What Accounts for the Rise in Medicare Spending? Kenneth E. Thorpe, Ph.D. Robert W. Woodruff Professor.

Chronic Disease Management Why is this an important issue? High numbers of patients affected Effective interventions may be available Concern that there.

Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.

Heart failure and comorbidities

Distribution of metabolic syndrome (MS) components by age and gender Zhao D, et al. Am J Cardiol 2007;100:835– 839.

The percentage of values for cardiac troponin (cTn)T associated with elevated values for a point-of-care assay with less sensitivity and precision: the.

Acute Myocardial Infarction Committee Membership : K. McLean, MD, M. Jarotkiewicz MBA, Administrative Director Cardiovascular Service Line, Mary Morrow,

Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.

The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.

Heart Failure Services at STH: How it works and how End of Life issues are addressed Dr Soon H Song Consultant Diabetologist Acute Medicine Lead for STH.

Angela Aziz Donnelly April 5, 2016

The FAVORIT Study (Folic Acid for Vascular Outcome Reduction in Transplantation) Source Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

R1. 최태웅 / Pf. 김정욱. INTRODUCTION Acute upper gastrointestinal bleeding (AUGIB) : incidence of 50–150 cases/100,000 : outcomes → by preexisting comorbidity,

Renal Replacement Therapy for Prevention of Contrast- induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials Source Song K, Jiang.

Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.

Preventive Measures Infection & Delayed Wound Healing Frequent dental visits to assess plaque control Risk assessment profiles to identify risk factors.

Diabetes mellitus.

The LIVES Sub-analysis

DIAGNOSIS No symptoms = no heart failure. DIAGNOSIS No symptoms = no heart failure.

Hypertension November 2016

The MASS-DAC Study.

by Thomas H. Marwick, and Markus Schwaiger Circ Cardiovasc Imaging

Stephen W. Waldo et al. JACC 2008;51:

Heart Failure and Hospital Readmissions

Cardiac Biomarkers.

HEART FAILURE QUALITY & CLINICAL CARE PROGRAMME

Biomarkers in Heart Failure

Heart Failure Management Coordinated Care Approaches

Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.

Health and Disease Management

Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

Biomarker-Guided HF Therapy: Is It Cost-Effective?

G. Michael Felker et al. JCHF 2014;2:

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Comorbidity status in patients with CKD stage 4 or 5 not on dialysis, peritoneal dialysis, haemodialysis and transplanted patients (bars), as well as in.

Both cardiovascular and non-cardiovascular diseases are important causes of death in dialysis patients: A comparison with the general population Minako.

Figure 2 Absolute difference in seasonal peak

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Hypertension November 2016

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Time to death from diabetes diagnosis for propensity-matched sample adjusted for age, gender, race, and other conditions. Time to death from diabetes diagnosis.

Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.

When we compared cardiac volumes (ED and ES) between those with high BNP levels (BNP >400 pg/mL) and low BNP (

Consultant Clinical Biochemist

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Increase of physical activity over time associated with lower HF risk

Glucose-lowering medication in type 2 diabetes: overall approach.

Presentation transcript:

The CHART-2 Study (The Chronic Heart Failure Analysis and Registry in the Tohoku District 2) Source Shiba N, Nochioka K, Miura M, et al. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan – first report from the CHART-2 study. Circ J. 2011;75(4):823–833.

Background Cardiovascular disorders are leading causes of mortality across the globe. Heart failure is the end stage of cardiovascular disorders and hospitalizations due to onset of acute heart failure is a key indicator of the prognosis of cardiovascular disorders. The CHART-2 study examined the etiological trends in patients with heart failure.

Aim The specific aims of the CHART-2 study were to elucidate/characterize: 1. Characteristics of patients with overt HF and the associated prognostic risks 2. Characteristics of patients at risk for HF and the factors associated with CVD progression 3. Factors associated with the development of AHFS 4. Prevalence and prognostic impact of metabolic syndrome (MetS) in patients with overt heart failure 5. The association between MetS and the development of AHFS 6. The prevalence and prognostic impact of malignancy in patients with CVD 7. The prevalence of patients needing home nursing care 8. The characteristics of bedridden patients with CVD

Methods

Key results The study established a clear trend of increasing prevalence of ischemic heart failure The plasma B-type natriuretic peptide (BNP) concentration was mildly elevated in patients with stage B heart failure and in those with CAD without overt HF. Furthermore, the cardiovascular risk profile were similar between groups The severity of prognostic risks such as reduced EF, elevated BNP, comorbidity of chronic kidney disease (CKD), and low hemoglobin levels exacerbated progressively as HF stage progressed Usage of standard medication was low, especially in the stage B patients (Fig. 1)

Conclusion The CHART-2 study demonstrated the trend of westernization of ischemic etiology and clinical characteristics of HF patients in Asian population, indicating the importance of appropriate management and prevention of CAD to prevent acute heart failure syndrome. Steps must be taken to ensure optimal usage of standard medications for prevention acute heart failure syndrome in patients with CAD.